MJ MEDTECH finished psilocybin extract in vivo animal trials

Written by ITW

November 25, 2020

Two years ago South African company MJ MEDTECH a subsidiary of WUHAN GENERAL GROUP INC. announced plans to enter psychedelic sector after successful cannabis and CBD endeavors. Tests are now complete for Rat and cell line trials with the focus now being pushed towards analyzing the data and putting it into meaningful words that can show the true applications of psilocybin. They are testing for brain chemistry, inflammation, overall health and long term affects. The goal of these studies is to prove the efficacy of psilocybin as a treatment for mental health (ptsd, depression, anxiety, etc) as well as other physical ailments (high blood pressure, brain inflammation etc). Human trials are now being scheduled in accordance with Covid 19 limitations. They currently have several successful cannabis products and will follow suit with extracts and fruiting bodies  when testing is complete.

Related Articles

The Future of Business and Psychedelics

What does it feel like to be a pioneer in an industry that doesn’t technically exist yet? Article by guest writer: Dennis Walker - mycopreneur I hosted the Future of Business and Psychedelics panel at the California Psychedelic Conference in Los Angeles on April 24th...

How To Get Spores In Michigan

Looking to get psychedelic mushroom spores in Michigan? Now that psilocybin containing mushrooms are decriminalized in some cities in Michigan, it is a great time to start your own research with mushroom spores.  Here’s everything you need to know about how to acquire...

The Difference Between Albino and Leucistic

What’s the difference between albino mushrooms and leucistic mushrooms? There has been some confusion within the mycology community about the difference between leucistic and albino mushrooms. In this article, we will break down the differences between the two and...

Stay Up to Date With The Latest News & Updates